| ID | 1205 |
| Name of the vaccine | EcSf2a-2 |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | NA |
| Description of the vaccine | This vaccine is an aro-D mutant derivative of EcSf2a-1. |
| Name of the manufacturer | NA |
| Name of the manufacturing country | NA |
| Year of manufacture | NA |
| Clinical Phase status | Clinical |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | Overall, the vaccine efficacy was 36%. |
| Vaccine formulation | NA |
| Dosage | Three doses. |
| Mechanism of action | IgA or IgG antibody titers recognizing purified LPS. |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Diarrhoea, dysentery and fever. |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=267&keywords= |
| Other name | NA |
| Additional Links | NA
|